摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Amino-5-(5-thiazolyl)-1,3,4-thiadiazole | 1377128-82-9

中文名称
——
中文别名
——
英文名称
2-Amino-5-(5-thiazolyl)-1,3,4-thiadiazole
英文别名
5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-amine
2-Amino-5-(5-thiazolyl)-1,3,4-thiadiazole化学式
CAS
1377128-82-9
化学式
C5H4N4S2
mdl
——
分子量
184.246
InChiKey
AKVBBVSZQVCUTA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    121
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    2-Amino-5-(5-thiazolyl)-1,3,4-thiadiazole三乙酰氧基硼氢化钠 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三氟乙酸 作用下, 反应 1.0h, 生成 (2S)-3-phenyl-2-(1,3-thiazol-4-ylmethylamino)-N-[5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-yl]propanamide
    参考文献:
    名称:
    Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes
    摘要:
    GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.08.015
  • 作为产物:
    描述:
    (1,3-Thiazole-5-carbonylamino)thiourea 在 PPA 作用下, 生成 2-Amino-5-(5-thiazolyl)-1,3,4-thiadiazole
    参考文献:
    名称:
    Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes
    摘要:
    GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.08.015
点击查看最新优质反应信息